ARA-290, also known as Cibinetide, is a synthetic 11-amino-acid peptide derived from the tissue-protective region of erythropoietin (EPO).<\/p>\n
Rather than stimulating red blood cell production like EPO, ARA-290 selectively activates the Innate Repair Receptor (IRR), a receptor complex that becomes active following tissue injury, inflammation or metabolic stress<\/strong>. This makes it one of the few research peptides designed specifically to investigate the body’s natural healing and repair response without affecting haematopoiesis<\/strong>.<\/p>\n Because of this unique mechanism, ARA-290 has attracted considerable attention in research involving peripheral nerve injury, inflammatory disorders, tissue protection and chronic pain<\/strong>.<\/p>\n Published research has investigated ARA-290 in relation to:<\/p>\n Unlike many recovery peptides that primarily investigate connective tissue regeneration, ARA-290 focuses on activating the body’s intrinsic repair pathways, particularly following inflammatory or neurological injury.<\/p>\n ARA-290 has one of the most distinctive mechanisms among healing peptides.<\/p>\n Activating the Innate Repair Receptor<\/strong><\/p>\n Rather than binding the classical erythropoietin receptor, ARA-290 selectively activates the Innate Repair Receptor (IRR), a receptor complex formed by the erythropoietin receptor and CD131.\u00a0Importantly, this receptor is expressed mainly after tissue damage or inflammatory stress, allowing researchers to investigate biological repair processes that are activated specifically during injury.<\/p>\n Supporting tissue protection<\/strong><\/p>\n Activation of the IRR has been associated with reduced inflammatory signalling, decreased cell death and improved tissue resilience in experimental models.\u00a0Unlike growth factors that stimulate cell proliferation, ARA-290 appears to support the body’s own repair mechanisms by restoring tissue homeostasis following injury.<\/p>\n Nerve repair research<\/strong><\/p>\n One of the strongest areas of published research involves small fiber neuropathy, where ARA-290 has demonstrated improvements in neuropathic symptoms together with evidence of small nerve fiber regeneration in early clinical studies.\u00a0This has established ARA-290 as one of the leading investigational peptides for nerve repair research.<\/p>\n Immune and inflammatory regulation<\/strong><\/p>\n Current evidence also suggests that activation of the Innate Repair Receptor can reduce excessive inflammatory signalling while promoting the transition from tissue injury toward physiological repair.<\/p>\n Many healing peptides investigate how tissues regenerate<\/strong>.<\/p>\n ARA-290 investigates how damaged tissues initiate repair<\/strong>.<\/p>\n Instead of primarily stimulating angiogenesis, collagen production or cell migration, ARA-290 focuses on activating the body’s innate repair response<\/strong> through the Innate Repair Receptor.\u00a0This unique biology has made it particularly interesting for research involving neurological injury, chronic inflammation and peripheral nerve disorders<\/strong>, where impaired repair mechanisms may contribute to long-term dysfunction.<\/p>\n ARA-290 is supported by both extensive preclinical research and early human clinical studies<\/strong>.<\/p>\n Published investigations have focused on small fiber neuropathy associated with sarcoidosis and type 2 diabetes, where improvements in neuropathic symptoms, autonomic function and evidence of corneal nerve fiber regeneration have been reported.<\/p>\n Researchers have also explored ARA-290 in models of ischemic injury, inflammatory disorders and metabolic disease, reflecting the broad biological role of the Innate Repair Receptor.<\/p>\n Although the findings are encouraging, larger placebo-controlled studies remain necessary to further define its clinical potential.<\/p>\n One of the principal goals behind the development of ARA-290 was to preserve erythropoietin’s tissue-protective properties while eliminating its effects on red blood cell production.<\/p>\n Early clinical studies have generally reported favourable tolerability without increases in haematocrit or haemoglobin. However, larger and longer-term human studies are still needed to fully characterise its safety profile.<\/p>\n Applicazione: ricerca di laboratorio e analitica Archiviazione<\/strong>flaconcini liofilizzati non aperti sono meglio conservati refrigerato a 2\u20138\u00b0C<\/strong>, che \u00e8 il metodo di conservazione confermato dal nostro partner di produzione e adatto fino a 24 mesi. Si preferisce la refrigerazione perch\u00e9 minimizza inutili cicli di congelamento-scongelamento durante la manipolazione di routine. Se \u00e8 necessaria una conservazione a termine sostanzialmente pi\u00f9 lungo, i flaconcini liofilizzati non aperti possono anche essere conservati congelati. Una volta ricostituita, conservare sempre a 2-8\u00b0C e non congelare.<\/p>\n ARA-290 is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. Must be reconstituted using appropriate laboratory technique. Due to its physicochemical properties, ARA-290 requires reconstitution with buffered saline<\/strong><\/a>. Inadequate pH conditions or improper handling may result in incomplete dissolution or a whitish\/opalescent appearance. To help preserve structural integrity, add the chosen solvent slowly against the inside wall of the vial rather than directly onto the peptide cake, and avoid vigorous shaking. Gentle swirling is generally sufficient once the peptide has fully dissolved. Standard laboratory practice also includes allowing refrigerated vials to reach room temperature before reconstitution to minimise condensation inside the vial.<\/p>\n Per altre indicazioni sulla scelta del solvente, sulla pianificazione della concentrazione e sullo stoccaggio, consultare il pieno Guida alla Ricostituzione dei Peptidi<\/a> e Calcolatore di Ricostituzione<\/a>.<\/p>\n Why choose our ARA-290?<\/strong><\/p>\n The landmark review describing the biology of the Innate Repair Receptor and the development of ARA-290 as a tissue-protective peptide.<\/p>\n A review summarising clinical and preclinical evidence supporting ARA-290 in peripheral nerve repair and neuropathy research.<\/p>\n One of the first clinical studies demonstrating improvements in neuropathic symptoms following ARA-290 treatment.<\/p>\n Modern reviews continue to investigate ARA-290 in inflammatory disease, metabolic dysfunction and neurological repair, highlighting the growing interest in Innate Repair Receptor biology.<\/p>\n What is ARA-290?<\/strong><\/p>\n ARA-290 (Cibinetide) is an 11-amino-acid peptide derived from erythropoietin. It is widely investigated as a healing peptide for nerve repair, tissue protection and innate repair signalling.<\/p>\n Why is ARA-290 considered a healing peptide?<\/strong><\/p>\n Unlike peptides that mainly stimulate tissue regeneration, ARA-290 investigates the biological pathways that activate the body’s own repair response after injury. This has made it an important research tool in tissue protection and recovery.<\/p>\n Why is ARA-290 different from erythropoietin?<\/strong><\/p>\n ARA-290 selectively activates the Innate Repair Receptor without activating the erythropoietin receptor responsible for red blood cell production. This allows researchers to investigate tissue protection independently of erythropoiesis.<\/p>\n How does ARA-290 differ from BPC-157?<\/strong><\/p>\n Although both are healing peptides, BPC-157 primarily investigates connective tissue repair and angiogenesis, whereas ARA-290 focuses on nerve repair, tissue protection and activation of innate repair pathways. Their mechanisms are complementary rather than overlapping.<\/p>\n What research areas commonly investigate ARA-290?<\/strong><\/p>\n Current research includes peripheral nerve injury, small fiber neuropathy, inflammatory signalling, tissue protection, autonomic dysfunction and metabolic injury.<\/p>\n Questo prodotto \u00e8 destinato all'uso umano?<\/strong><\/p>\n No. ARA-290 supplied by LIFE Peptide is intended strictly for laboratory and analytical research. It is not intended for human consumption, diagnosis, treatment or prevention of disease.<\/p>\n ARA-290 is frequently discussed alongside other healing peptides investigating recovery, tissue repair and inflammation, although each peptide targets a different aspect of the healing process.<\/p>\n BPC-157<\/strong> <\/a>\u2013 investigated primarily for connective tissue healing, tendon biology, angiogenesis and gastrointestinal repair. While these peptides all contribute to healing research, ARA-290 stands apart through its selective activation of the Innate Repair Receptor and its strong focus on nerve repair and tissue protection.<\/p>\n
\nWhy ARA-290 is widely investigated<\/strong><\/h4>\n
\n
How ARA-290 works<\/strong><\/h4>\n
\nWhy ARA-290 is different from other healing peptides<\/strong><\/h4>\n
Ricerca umana e preclinica<\/strong><\/h4>\n
Osservazioni di sicurezza pubblicate<\/strong><\/h4>\n
\nCaratteristiche del prodotto<\/strong><\/h4>\n
\nUso limitato: non per il consumo umano; non per uso medico, veterinario o cosmetico
\nProdotto in stabilimenti conformi alle GMP secondo rigidi protocolli di controllo qualit\u00e0.
\nOgni lotto viene accuratamente testato in laboratorio dopo la produzione (puoi trovare il Certificato di Analisi sotto le immagini del prodotto).
\nLiofilizzato (liofilizzato) per la massima stabilit\u00e0 e una lunga durata di conservazione.
\nSigillato in fiale sterili, pronto per la ricostituzione.
\nPurity: \u226599% (HPLC-tested)
\nAspetto: polvere liofilizzata bianca\/bianco sporco
\nFormula molecolare: C51<\/sub>H84<\/sub>N16<\/sub>O21<\/sub>
\nMolecular weight: 1257.31
\nSequence: Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser<\/p>\nRicostituzione e manipolazione<\/strong><\/h4>\n
\n\n
\nRicostituzione<\/strong>: Must be reconstituted using appropriate laboratory technique. Due to its physicochemical properties, ARA-290 requires reconstitution with buffered saline<\/a>. Inadequate pH conditions or improper handling may result in incomplete dissolution or a whitish\/opalescent appearance.<\/li>\n<\/ul>\n
\nRiferimenti di ricerca selezionati<\/strong><\/h4>\n
\n
\n
\n
\n
\nDomande Frequenti<\/strong><\/h4>\n
Contesto di ricerca correlato<\/strong><\/h4>\n
\nTB-500<\/strong><\/a> (Thymosin \u03b24) \u2013 studied for cell migration, regeneration and wound healing.
\nKPV<\/strong> <\/a>\u2013 focuses on immune regulation and inflammatory signalling, particularly in gut and epithelial tissues.
\nGHK-Cu<\/strong><\/a> \u2013 investigated for extracellular matrix remodelling, skin repair and tissue regeneration.
\nWolverine Blend<\/strong><\/a> \u2013 combines BPC-157 and TB-500 for multi-pathway connective tissue recovery research.
\nSS-31<\/strong> <\/a>\u2013 studied for mitochondrial protection and cellular resilience.<\/p>\n